Taken together, these data suggest that intratumoral administration of immRNA‐RBCEVs triggers anti‐tumour responses by activating the RIG‐I pathway and recruiting immune cells for orthotopic and xenograft breast cancer suppression. Here, RIGI is linked to breast carcinoma.